💊
Paxneury
guanfacine
Uppmärksamhetsstörning med hyperaktivitet
✅ Auktoriserad
Generisk
✅
Inga aktiva aviseringar
Denna medicin har inga pågående brister, säkerhetsbrev eller återkallelser.
Vad det används till
Paxneury is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents 6‑17 years old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective. Paxneury must be used as a part of a comprehensive ADHD treatment programme, typically including psychological, educational and social measures.
⚠️ Patientsäkerhet
No
Officiell EMA-sida
https://www.ema.europa.eu/en/medicines/human/EPAR/paxneury